MNC：退回一个RAS。又从中国引进一个RAS候选新药(大跌)

Group 1 - The core point of the article is the collaboration agreement between JACOBI Pharma and AstraZeneca regarding the development and commercialization of the Pan-KRAS inhibitor JAB-23E73, with AstraZeneca obtaining exclusive rights outside of China [1][19] - Under the terms of the agreement, JACOBI Pharma will receive an upfront payment of $100 million and is eligible for up to $1.915 billion in milestone payments related to development and commercialization, as well as tiered royalties on net sales outside of China [1][19] - AstraZeneca will be responsible for all clinical development, regulatory submissions, and commercialization activities for JAB-23E73 in markets outside of China [1][19] Group 2 - JAB-23E73 is an innovative Pan-KRAS inhibitor developed by JACOBI Pharma, targeting multiple KRAS mutation subtypes, with KRAS being the most common mutated oncogene in humans, present in approximately 23% of all patients [3][21] - The drug is currently undergoing Phase I clinical trials in both China and the United States [3][21] Group 3 - The competitive landscape for Pan-KRAS inhibitors shows JACOBI Pharma leading with 87 priority applications, followed by other companies like BMS (Mirati) with 21 and Pfizer with 15 [7][25]